Substance and claimed effects

This entry covers the symptom and laboratory patterns that distinguish inflammatory bowel disease (IBD) — Crohn's disease and ulcerative colitis — from irritable bowel syndrome (IBS), and the downstream effects of recognising those patterns early. IBS is a functional disorder of gut–brain signalling with no structural damage; IBD is chronic immune-mediated inflammation that, untreated, destroys the bowel wall over years. The two overlap heavily at the symptom front door — both cause cramping, bloating, and altered stool. The red flags ("alarm features" in the guideline literature) are the specific clinical signals that should redirect a patient from the IBS pathway to urgent gastroenterology referral and objective testing Maaser et al. 2019 Rome IV 2016. Recognising them earlier compresses the diagnostic delay — currently a median of ~5 months for ulcerative colitis and 9–12 months (tail running into years) for Crohn's Schoepfer et al. 2013 Pellino et al. 2015. The claimed effects cluster: less progression to stricturing/fistulising Crohn's, fewer emergency surgeries, less colorectal cancer risk in long-standing colitis, better day-to-day quality of life on effective therapy, and meaningful reductions in IBD-associated anxiety and depression. Action class is respond (trigger-based; not a daily habit).

Evidence by addressing question

mechanism

IBS is a disorder of gut–brain interaction: visceral hypersensitivity, altered motility, and microbiome–immune signalling, with intact mucosa on endoscopy and normal inflammatory markers Rome IV 2016. IBD is structural: in ulcerative colitis, continuous mucosal inflammation from the rectum proximally; in Crohn's, transmural patchy inflammation anywhere from mouth to anus, with a strong predilection for the terminal ileum and perianal tissue Lichtenstein et al. 2018 Rubin et al. 2019. The red flags are clinical surrogates for that structural process. Rectal bleeding reflects ulcerated mucosa; IBS does not cause it (bright-red streaking from haemorrhoids is the common confounder). Nocturnal symptoms — diarrhoea, pain, or stool urgency that wakes the patient — track tissue inflammation that ignores circadian motility patterns; IBS symptoms cluster in waking hours. Unintentional weight loss, fever, and night sweats reflect systemic inflammatory cytokine load and (in Crohn's ileitis) malabsorption. Iron-deficiency anaemia arises from chronic occult blood loss plus inflammation-driven iron sequestration. Perianal disease — fissures off the midline, fistulas, abscesses, skin tags — is essentially diagnostic of Crohn's in someone with chronic bowel symptoms. Extraintestinal manifestations — peripheral or axial arthritis, episcleritis/uveitis, erythema nodosum, pyoderma gangrenosum, primary sclerosing cholangitis — occur in roughly 25–40% of IBD patients and frequently precede gut diagnosis Vavricka et al. 2015. Onset after age 50, and family history of IBD, both raise pre-test probability sharply. The mechanism story matters because it explains why a normal symptom cluster (cramping + altered stool) plus any red flag is no longer an IBS picture, regardless of how well the symptoms otherwise fit Rome IV.

evidence

Three evidence threads anchor the case for systematic red-flag screening: diagnostic delay data, fecal calprotectin diagnostic performance, and outcomes of early effective therapy.

Diagnostic delay. A prospective Swiss IBD cohort (n=905) found median diagnostic delay of 9 months in Crohn's vs 4 months in ulcerative colitis, with the top quartile of Crohn's patients waiting more than 2 years; delay above the median was independently associated with bowel stenosis (odds ratio ~1.8), internal fistulas, and surgery Schoepfer et al. 2013. An Italian cohort replicated the pattern: longer pre-diagnosis interval correlated with stricturing/penetrating disease behaviour at diagnosis rather than the inflammatory-only pattern that responds best to medical therapy Pellino et al. 2015. The natural-history cohort from Saint-Antoine (n=2,002) showed Crohn's disease behaviour shifting from inflammatory to stricturing or penetrating in roughly 50% of patients within 10 years of diagnosis; earlier diagnosis lengthens the window in which medical therapy can hold the inflammatory phenotype Cosnes et al. 2002.

Fecal calprotectin. The neutrophil cytosolic protein leaks into stool in proportion to mucosal inflammation. A diagnostic meta-analysis (13 studies, n=1,041 adults) found pooled sensitivity 93% and specificity 96% for distinguishing IBD from non-IBD bowel symptoms, with an estimated 67% reduction in unnecessary colonoscopies if used as a triage gate van Rheenen et al. 2010. NICE diagnostic guidance DG11 recommends calprotectin as a primary-care option to distinguish IBD from IBS in adults with lower-GI symptoms in whom cancer is not suspected NICE DG11 2013. ECCO–ESGAR consensus places calprotectin alongside CRP and full blood count as the standard initial laboratory work-up when IBD is on the differential Maaser et al. 2019. Operating thresholds: <50 µg/g effectively rules out IBD in symptomatic adults; >250 µg/g raises strong suspicion; the 50–250 µg/g grey zone usually warrants repeat testing or endoscopy. CRP is less sensitive (a meaningful minority of active Crohn's, especially isolated ileal disease, runs CRP-negative) and should not be used alone to exclude IBD Vermeire et al. 2006.

Early effective treatment changes the disease course. The Step-up vs Top-down trial randomised newly diagnosed Crohn's patients to early combined immunosuppression (infliximab + azathioprine) vs conventional sequential therapy; the early-aggressive arm had higher steroid-free remission at week 26 (60% vs 36%) and at week 52 (62% vs 42%) D'Haens et al. 2008. The CALM trial used objective biomarkers (CRP and calprotectin) to drive treatment escalation in Crohn's and showed superior mucosal healing at 48 weeks vs symptom-driven management (46% vs 30%) Colombel et al. 2017. These trials do not show that the red-flag triage step itself changes outcomes — that link is indirect, via earlier diagnosis enabling earlier treatment — but they establish the downstream value of compressing time-to-effective-therapy.

protocol

Clinical workup when red flags appear in a chronic-bowel-symptom presentation, drawn from ECCO–ESGAR and ACG guidelines Maaser et al. 2019 Lichtenstein et al. 2018 Rubin et al. 2019:

• Initial bloods: full blood count (anaemia, thrombocytosis), CRP, ferritin and iron studies, vitamin B₁₂ and folate, albumin, liver function tests (PSC screening), TSH, coeliac serology.
• Fecal calprotectin as the inflammatory-vs-functional discriminator. A symptomatic adult with calprotectin under 50 µg/g and no overt rectal bleeding is reassuringly non-IBD; above 250 µg/g mandates endoscopic evaluation.
• Stool cultures, C. difficile, and ova/parasites to exclude infectious mimics before colonoscopy.
• Ileocolonoscopy with terminal ileum intubation and segmental biopsies remains the diagnostic gold standard Maaser et al. 2019. Sigmoidoscopy alone misses isolated right-sided and ileal Crohn's.
• Small-bowel imaging (MR enterography or capsule endoscopy) for suspected Crohn's with normal colonoscopy or to assess disease extent.
• Referral timing: any of the red flags + chronic bowel symptoms warrants gastroenterology referral on a 2–4 week timeline; rectal bleeding with weight loss or anaemia is a 2-week urgent referral in most national pathways.

stakes

Untreated or under-recognised IBD progresses on a known trajectory. In Crohn's, the inflammatory phenotype shifts over ~10 years toward stricturing (bowel narrowing causing obstruction) or penetrating (fistulas, abscesses) behaviour in roughly half of patients, with cumulative surgery rates of 30–50% at 10 years from diagnosis Cosnes et al. 2002 Pariente et al. 2011. In ulcerative colitis, colectomy rates are ~15% at 10 years, higher with extensive disease; long-standing extensive colitis (>8 years) carries a colorectal cancer risk roughly 2–3× the general population, with surveillance colonoscopy recommended from year 8 of disease Beaugerie & Itzkowitz 2015 Rubin et al. 2019. IBD also carries a roughly 2× lifetime risk of depression and anxiety vs general population, with active inflammation strongly correlated with both Mikocka-Walus et al. 2016. The felt-experience layer: chronic urgency, accidents, fatigue, joint pain, skin lesions, eye flares — the disease bleeds into work, relationships, and the patient's sense of agency long before structural complications force surgery.

misconceptions

• "IBS that's getting worse" is not a diagnosis. IBS is a stable functional pattern. Progressive worsening, especially with any red flag, is by definition incompatible with the IBS label and demands re-evaluation Rome IV 2016.
• "You're too young / too healthy / too high-functioning for IBD." IBD's peak incidence is age 15–35, with a smaller second peak at 50–70 Burisch et al. 2013. Athletes, professionals, and the otherwise-fit are over-represented in delayed-diagnosis cohorts because clinicians anchor on demographic priors.
• "Bleeding is just haemorrhoids." Sometimes true, often not. Haemorrhoidal blood is bright-red streaking on paper or stool surface; mixed-in dark blood, blood with mucus, or blood with diarrhoea is mucosal and warrants workup.
• "Normal CRP rules out IBD." Roughly 20% of active Crohn's, particularly isolated ileal disease, runs CRP-negative Vermeire et al. 2006. Calprotectin is the better single laboratory discriminator.
• "Normal sigmoidoscopy is reassuring." A flexible sigmoidoscopy that stops at the splenic flexure misses isolated right-sided and ileal Crohn's. Full ileocolonoscopy with terminal ileum intubation is the diagnostic standard Maaser et al. 2019.

audience

Two subgroups bear disproportionate delay. Young women presenting with abdominal pain and altered stool are systematically more likely to be labelled with IBS, anxiety, or a functional disorder before structural workup is pursued; the Swiss cohort's diagnostic-delay distribution skews longer in women Schoepfer et al. 2013. People who present primarily with extraintestinal symptoms — peripheral arthritis, recurrent uveitis or episcleritis, erythema nodosum, primary sclerosing cholangitis on routine LFTs — often loop through rheumatology, ophthalmology, dermatology, or hepatology before anyone systematically asks about bowel symptoms; up to 25% of IBD patients have an extraintestinal manifestation before, or instead of, prominent gut symptoms at first presentation Vavricka et al. 2015.

failure-modes

• Labelled IBS, no objective testing. Rome IV is a positive-diagnosis criterion explicitly contingent on the absence of alarm features Rome IV 2016. An IBS label given without a calprotectin (and, where indicated, endoscopy) is doing the wrong job.
• Empirical treatment masking the picture. Antispasmodics, low-FODMAP diets, antidepressants, and over-the-counter loperamide can partially blunt symptoms of mild IBD and delay diagnosis for months to years.
• Single-snapshot reassurance. One normal calprotectin in a patient with persisting red flags doesn't close the door; mild or patchy Crohn's can have intermittent calprotectin elevations. Repeat the test if symptoms persist.
• "Stress colitis" framing. Attributing symptoms to anxiety or work stress is plausible-sounding but actively harmful when red flags are present. The two coexist; one doesn't rule out the other.

out-of-scope

Forward-pointers worth naming for the reader without dwelling: positive IBS diagnosis (Rome IV criteria, low-FODMAP trial, gut–brain axis pharmacotherapy), coeliac screening, colonoscopy as a procedure, iron-deficiency anaemia workup, microscopic colitis (an under-diagnosed cause of chronic watery diarrhoea in older adults), and the IBD treatment ladder (5-ASAs → immunomodulators → anti-TNF and other biologics → JAK inhibitors → surgery). These each warrant their own entries.

Credibility range

Optimist case

The red-flag list and the calprotectin triage gate are well-evidenced, low-controversy, guideline-backed across ACG, ECCO, NICE, and BSG. The intervention is essentially free (recognition + a non-invasive stool test) and the downstream value of earlier IBD diagnosis — earlier effective therapy, better treatment response, fewer surgeries, lower long-term complication rate — is supported by multiple RCTs (Step-up vs Top-down, CALM) and large prospective cohorts D'Haens et al. 2008 Colombel et al. 2017 Schoepfer et al. 2013. Calprotectin's diagnostic performance (sensitivity 93%, specificity 96%) is among the highest of any non-invasive GI test van Rheenen et al. 2010. The case for reader awareness is unusually clean: knowing the red flags compresses time-to-diagnosis, the cost of action is trivial, and the downside of inaction is large and well-mapped.

Skeptic case

The link from "patient recognises a red flag" to "patient gets diagnosed earlier" is mostly observational. No RCT has randomised public awareness campaigns and measured time-to-IBD-diagnosis. The trial evidence anchors the value of early effective treatment, not the value of patient-level red-flag recognition. There is a real risk of inducing health anxiety in the much larger IBS population (10–15% prevalence) who will read about red flags and worry; calprotectin testing for every cramping adult would create capacity strain and over-investigate the bulk of IBS. Some red flags (mild nocturnal symptoms, single episode of bright-red bleeding) have low positive predictive value in isolation. And patient agency is bounded: many delays sit on the clinician side (dismissive consults, anchoring on demographic priors), not the patient side, so reader education isn't the binding constraint.

Author's call

The evidence base for the laboratory and clinical workflow is strong (evidence: 5); the controversy in the field is low (controversy: 1) — the red-flag list and calprotectin's role are not contested. The author's call: this entry is worth writing as a respond entry — when a reader sees one or more red flags alongside chronic bowel symptoms, the right move is to push for objective testing rather than accept an IBS label. The skeptic case correctly notes that reader education isn't the only lever, but it is a lever the reader controls. Honest framing should anchor on the typical "IBS-labelled patient who is quietly getting worse," not on the dramatic case. The known harm of over-worrying mild functional symptoms is real but manageable — the red flag set is specific enough (blood, weight loss, nocturnal symptoms, anaemia, fever, perianal disease, family history, late onset, extraintestinal signs) that healthy adults with garden-variety bloating won't trigger it.

Stakeholder and incentive map

• Gastroenterology and IBD specialists — broadly aligned with patient-side awareness; earlier referrals fit their treat-to-target paradigm.
• Primary care — variable. UK NICE pathways have institutionalised calprotectin; US primary care use is patchier, with cost and lab availability driving practice.
• Calprotectin assay manufacturers — commercial incentive to expand use; doesn't undermine the evidence, but worth naming.
• IBD pharmaceutical sector (anti-TNF, IL-23, integrin, JAK inhibitor manufacturers) — strong commercial alignment with earlier diagnosis; sponsors much of the "window of opportunity" literature. The trial data (CALM, Step-up vs Top-down) are real and pre-registered, but the framing of "early aggressive" therapy has industry-aligned amplification.
• Functional GI / IBS specialists — push back against pan-calprotectin screening on capacity and cost grounds. Not against the red-flag list, which is in their own diagnostic criteria.
• Patient advocacy organisations (Crohn's & Colitis Foundation, Crohn's & Colitis UK) — actively campaign on diagnostic delay and red-flag awareness.

Population variability

• Age. Bimodal incidence: a large peak at 15–35 and a smaller peak at 50–70 Burisch et al. 2013. Late-onset symptoms (after 50) are themselves an alarm feature in the IBS criteria.
• Sex. Crohn's slightly female-predominant; UC roughly equal. Diagnostic delay is consistently longer in women, likely reflecting anchoring on functional or anxiety diagnoses Schoepfer et al. 2013.
• Family history. First-degree relative with IBD raises lifetime risk roughly 5–10×; shifts the threshold for workup downward.
• Smoking status. Active smoking increases Crohn's risk and worsens its course; the opposite for ulcerative colitis, where smoking is paradoxically protective and quitting can trigger flares.
• Geography and ancestry. Historically higher prevalence in Northern Europe, North America, and Ashkenazi Jewish populations, but incidence is rising sharply in Asia, South America, and the Middle East with urbanisation; assumptions about "low-risk" ethnic backgrounds are increasingly outdated Burisch et al. 2013.
• Extraintestinal-predominant presentation. ~25% of IBD patients present first to a non-GI specialty (rheumatology, ophthalmology, dermatology, hepatology) Vavricka et al. 2015.

Knowledge gaps

• No RCT directly tests whether patient-level red-flag awareness changes time-to-diagnosis; the chain is inferred from delay-outcomes studies plus early-treatment trials.
• Calprotectin's grey zone (50–250 µg/g) is operationally unclear — retest interval and threshold for moving to endoscopy vary across guidelines.
• The proportion of IBS-labelled patients who actually have undiagnosed mild IBD is not well-quantified; estimates from screening cohorts range from 1–3% depending on calprotectin threshold and follow-up duration.
• Whether very early intervention in the inflammatory-only Crohn's phenotype (the so-called "window of opportunity") changes the natural-history trajectory of stricturing/penetrating disease is mechanistically plausible and observationally supported, but the prospective RCT evidence is still maturing.
• Sex- and race-stratified diagnostic-delay data are limited outside European cohorts; the magnitude of the women-and-people-of-colour delay gap in US, Asian, and Middle Eastern populations is underspecified.

Brief vs scope. The topic brief named Crohn's and ulcerative colitis as the IBD pair and pointed at three downstream consequences: time to diagnosis, complications, and treatment escalation. The article covers all three — diagnostic delay data in evidence; stricturing/penetrating progression, colectomy, and cancer risk in stakes; the inferred-but-not-RCT'd link between earlier diagnosis and earlier-effective therapy in evidence and payoff. No narrowing relative to the brief.

Action choice. Considered know (awareness only) vs respond (protocol when a symptom appears). Picked respond — the action set is concrete (ask for fecal calprotectin and a blood panel by name, push for GI referral on the 2–4 week pathway), not just recognition. respond + as-needed matches a trigger-based action better than know + once.

Score calls worth flagging.

• health_short_term at 4. Scored against the affected subset (someone going from undiagnosed active IBD to evidence-based induction), not the general reader. The lift is transformative on the relevant subgroup but only ~1–3% of the IBS-labelled population actually has IBD; the score reflects the effect when the entry applies. Could defensibly drop to 3 if the rating frame is "average across all readers who triggered on a red flag and got tested."
• beauty_cumulative at 1. Borderline. The effect chain is distal — recognising red flags → earlier diagnosis → less chronic-inflammation pallor, less weight loss, less perianal scarring, less long-term steroid exposure. Defensibly 0 if a stricter "direct effect of the substance" reading is applied. Held at 1 for honesty about the cumulative aesthetic toll of untreated disease.
• focus at 0. IBD-related anaemia and inflammation do impair cognition, but the link from "knowing the red flags" to focus is two steps removed. 0 is the honest call.
• longevity at 3, not 4. The mortality / cancer-prevention effect is real but not dominant against the catalogue's largest longevity levers (smoking, cardiovascular risk, screening colonoscopy in the general population). 3 (meaningful disease-prevention) is the right anchor.

Excluded by design.

• Positive IBS diagnostic criteria, low-FODMAP detail, gut–brain pharmacotherapy. These belong in a sibling IBS entry.
• Colonoscopy as a procedure — prep, sedation, what the report means. Mentioned in protocol but not detailed. Own entry.
• The IBD treatment ladder (5-ASAs, immunomodulators, anti-TNF, IL-23, integrin inhibitors, JAK inhibitors, surgery). Out of scope here; the entry's job is the diagnostic doorway. Own entry.
• Microscopic colitis — distinct condition, distinct workup (needs biopsies on an otherwise-normal colonoscopy), worth its own entry. Flagged in out-of-scope.
• Iron-deficiency anaemia workup as a standalone topic. Touched in mechanism and protocol; the broader workup deserves its own entry.
• Paediatric IBD presentation. Brief is adult-oriented; paediatric workflow (growth failure, distinct calprotectin thresholds, dietary therapy as induction) is a different entry.

Future-link candidates. When these entries land, this one should cross-link: ibs-positive-diagnosis, colonoscopy, fecal-calprotectin (if granular enough to warrant its own page), iron-deficiency-anaemia-workup, microscopic-colitis, ibd-treatment-ladder, possibly extraintestinal-manifestations-of-ibd.

Audience scoping. Considered scoping the whole entry to female given the well-documented diagnostic-delay gap, but rejected — IBD's bimodal age distribution and roughly equal UC sex ratio make a universal-audience entry correct. The audience section carries a female-scoped sub-block for the specific delay pattern, which is the right granularity.

Evidence note. The chain from "reader recognises red flag" to "diagnosis sped up" is observational; no RCT directly tests reader-side awareness against time-to-diagnosis. The evidence rating (5) anchors on the laboratory and clinical workflow's evidence base (calprotectin meta-analysis, multiple guideline endorsements, RCTs on early effective therapy), not on the awareness-to-action link itself. Flagged inside evidence section.